CJC-1295
Also known as: CJC-1295 no DAC · Modified GRF 1-29
CJC-1295 is a popular peptide topic online, but it is not FDA-approved for human use. Use this guide to understand the claims, the evidence gaps, and the safety questions to ask before considering anything further.
The DAC version has some published human data. The no-DAC version is mostly extrapolated. Mechanistic evidence is sound but clinical outcomes data is sparse.
What to know before you go deeper
A growth-hormone-releasing peptide topic often discussed with ipamorelin. People usually ask about it for recovery, sleep, and body-composition goals.
Approval status: Not FDA-approved. This is not an FDA-approved human treatment.
Growth hormone research, Body recomposition, Recovery.
What evidence applies to my situation, what monitoring is needed, and what safer first steps should I try?
Why People Ask About CJC-1295
- Growth hormone research
- Body recomposition
- Recovery
- Anti-aging
Questions to Bring Up
Often discussed with ipamorelin in wellness settings, but use patterns vary and are not FDA-approved. Ask a clinician about evidence limits and safety monitoring.
Dosing, sourcing, and suitability questions belong with a licensed clinician who can review your history, labs, medications, and goals.
Known Side Effects
- Water retention
- Headache
- Flushing (transient)
- Injection site reactions
Important Safety Notes
⚠ Research use only — not approved for human use
The "with DAC" version has a much longer half-life and different pulse characteristics — these are distinct compounds
Typically used in combination with ipamorelin, not alone
What Is Approved?
Not FDA-approved for human use. The "no DAC" version has a shorter half-life and is usually discussed differently than the longer-acting version.
Your feedback helps us improve the guide.